Fatigue and Other Patient-Reported Outcomes in Patients With RRMS who Switched to Ocrelizumab: 4-Year Data From CASTING-LIBERTO

被引：1
作者：
Kister, Ilya [1 ]
Benedict, Ralph [2 ]
Comi, Giancarlo [3 ,4 ]
Cutter, Gary [5 ]
Oreja Guevara, Celia [6 ]
Clinch, Susanne [7 ]
Kuenzel, Thomas [8 ]
Dirks, Petra [8 ]
Vermersch, Patrick [9 ]
机构：
[1] NYU, Multiple Sclerosis Comprehens Care Ctr, Langone Med Ctr, New York, NY USA
[2] SUNY Buffalo, Dept Neurol, Jacobs Sch Med & Biomed Sci, Buffalo, NY USA
[3] Univ Vita Salute San Raffaele, Milan, Italy
[4] Casa Cura Policlin, Milan, Italy
[5] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL USA
[6] Hosp Clin San Carlos, Madrid, Spain
[7] Roche Prod Ltd, Welwyn Garden City, England
[8] F Hoffmann La Roche Ltd, Basel, Switzerland
[9] Univ Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France
来源：
NEUROLOGY | 2023年 / 100卷 / 17期
关键词：
D O I：
10.1212/WNL.0000000000202199
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P6-3.010
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Efficacy and safety of ocrelizumab is maintained in patients with RRMS with suboptimal response to prior disease-modifying therapies: 4-year NEDA data from CASTING-LIBERTO
    Oreja-Guevara, C.
    Benedict, R. H.
    Comi, G.
    Cutter, G.
    Kister, I.
    Siva, A.
    Wiendl, H.
    Van Wijmeersch, B.
    Wuerfel, J.
    El Azzouzi, B.
    Buffels, R.
    Dirks, P.
    Kuenzel, T.
    Vermersch, P.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 327 - 329
  • [2] Improvements in patient-reported symptomscreen scores among ocrelizumab-treated patients with rrms: 2-year results from the casting clinical trial
    Kister, I.
    Cutter, G.
    Buffels, R.
    Clinch, S.
    Kuenzel, T.
    Vermersch, P.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 610 - 610
  • [3] Efficacy and safety of ocrelizumab in patients with RRMS with suboptimal response to prior disease-modifying therapies: 3-year data from CASTING and LIBERTO 1-year interim results
    Van Wijmeersch, B.
    Comi, G.
    Oreja-Guevara, C.
    Wiendl, H.
    Wuerfel, J.
    Buffels, R.
    Dirks, P.
    Kuenzel, T.
    Kadner, K.
    Vermersch, P.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 543 - 544
  • [4] Comparing 4-Year Changes in Patient-Reported Outcomes Following Ankle Arthroplasty and Arthrodesis
    Sangeorzan, Bruce J.
    Ledoux, William R.
    Shofer, Jane B.
    Davitt, James
    Anderson, John G.
    Bohay, Donald
    Coetzee, J. Chris
    Maskill, John
    Brage, Michael
    Norvell, Daniel C.
    JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2021, 103 (10) : 869 - 878
  • [5] Characteristics and patient-reported outcomes of patients initiating ocrelizumab in the narcoms registry from 2017 to 2019
    Salter, A.
    Lancia, S.
    Marrie, R. A.
    Fox, R.
    Engmann, N.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 596 - 597
  • [6] Functional Assessment of Fatigue and Other Patient-Reported Outcomes in Patients Enrolled in the Global aHUS Registry
    Greenbaum, Larry A.
    Licht, Christoph
    Nikolaou, Vasileios
    Al-Dakkak, Imad
    Green, Janet
    Haas, Christian Stefan
    Roman-Ortiz, Elena
    Cheong, Hae Il
    Sartz, Lisa
    Swinford, Rita
    Tomazos, Ioannis
    Miller, Benjamin
    Cataland, Spero
    KIDNEY INTERNATIONAL REPORTS, 2020, 5 (08): : 1161 - 1171
  • [7] Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA
    van der Heijde, Desiree
    Dougados, Maxime
    Landewe, Robert
    Sieper, Joachim
    Maksymowych, Walter P.
    Rudwaleit, Martin
    Van den Bosch, Filip
    Braun, Juergen
    Mease, Philip J.
    Kivitz, Alan J.
    Walsh, Jessica
    Davies, Owen
    Bauer, Lars
    Hoepken, Bengt
    Peterson, Luke
    Deodhar, Atul
    RHEUMATOLOGY, 2017, 56 (09) : 1498 - 1509
  • [8] Sleep disturbance in patients with rheumatoid arthritis is related to fatigue, disease activity, and other patient-reported outcomes
    Austad, C.
    Kvien, T. K.
    Olsen, I. C.
    Uhlig, T.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2017, 46 (02) : 95 - 103
  • [9] CERTOLIZUMAB PEGOL IS ASSOCIATED WITH LONG-TERM IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PSORIATIC ARTHRITIS: 4-YEAR OUTCOMES FROM THE RAPID-PSA STUDY
    Gladman, D.
    Fleischmann, R.
    Harris, K.
    Peterson, L.
    Mease, P. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 673 - 673
  • [10] CERTOLIZUMAB PEGOL IS ASSOCIATED WITH LONG-TERM IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PSORIATIC ARTHRITIS: 4-YEAR OUTCOMES FROM THE RAPID-PSA STUDY
    Gladman, D.
    Fleischmann, R.
    Harris, K.
    Peterson, L.
    Mease, P. J.
    VALUE IN HEALTH, 2016, 19 (07) : A594 - A594
12345